证券代码：688617 证券简称：惠泰医疗 公告编号：2023-039 深圳惠泰医疗器械股份有限公司 关于参加 2023 年深圳辖区上市公司投资者网上 集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，深圳惠泰医疗器械股份有限公司（以下 简称“公司”）将参加由深圳证监局指导、深圳上市公司协会与深圳市全景网络 有限公司联合举办的“2023年深圳辖区上市公司投资者网上集体接待日”活动， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 11 月 15 日（周三）14:00-17:00。届时公 司管理层将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 特此公告。 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥425,724,057.78, representing a year-over-year increase of 28.36%[3] - Net profit attributable to shareholders for Q3 2023 was ¥145,851,907.54, up 43.41% compared to the same period last year[3] - The net profit attributable to shareholders for the year-to-date period increased by 54.75% to ¥403,247,364.38[3] - Total revenue for the first three quarters of 2023 reached ¥1,213,709,560.43, a significant increase from ¥887,326,586.93 in the same period of 2022, representing a growth of approximately 37%[20] - Net profit for the first three quarters of 2023 was ¥396,563,367.77, compared to ¥247,647,452.87 in 2022, reflecting a growth of approximately 60%[21] - The total comprehensive income for the first three quarters of 2023 reached ¥410,753,518.73, a significant increase from ¥251,542,519.97 in the same period of 2022, representing a growth of approximately 63.2%[22] Cash Flow - The net cash flow from operating activities for Q3 2023 was ¥153,245,429.08, reflecting a significant increase of 53.74% year-over-year[3] - The net cash flow from operating activities for the first three quarters of 2023 was ¥484,558,878.95, compared to ¥279,573,710.23 in 2022, marking an increase of approximately 73.3%[24] - Cash inflows from operating activities amounted to ¥1,338,983,063.61, up from ¥993,852,461.75 in the previous year, indicating a growth of about 34.7%[23] - The company reported a net cash outflow from investing activities of ¥47,913,952.10, an improvement from a net outflow of ¥100,036,590.11 in the previous year[24] - The net cash flow from financing activities was negative at -¥238,959,527.67, compared to -¥102,908,293.69 in the same period of 2022, indicating increased cash outflows[24] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,444,095,423.27, a growth of 9.80% compared to the end of the previous year[4] - The company's total liabilities as of September 30, 2023, amounted to ¥606,572,229.18, an increase from ¥434,912,807.26 at the end of 2022, marking a rise of about 39%[19] - Current assets totaled RMB 1,673,178,348.37, up from RMB 1,557,457,712.49, indicating an increase of about 7.4%[17] - Cash and cash equivalents amounted to RMB 451,530,046.17, compared to RMB 250,881,142.52 at the end of 2022, representing an increase of approximately 80.1%[16] - The total assets of the company as of September 30, 2023, were ¥2,444,095,423.27, up from ¥2,225,978,346.27 at the end of 2022, marking an increase of approximately 10%[19] Research and Development - Research and development expenses totaled ¥59,389,169.44 for Q3 2023, marking a 29.24% increase year-over-year[4] - Research and development expenses for the first three quarters of 2023 were ¥168,316,723.06, compared to ¥134,322,322.41 in 2022, indicating an increase of approximately 25%[20] - The proportion of R&D expenses to revenue was 13.95%, a slight increase of 0.10 percentage points compared to the previous year[4] Market Strategy - The company plans to continue expanding its market presence and enhancing brand recognition through ongoing marketing activities[7] - The company is focusing on expanding its market presence and enhancing product development capabilities, although specific new products or technologies were not detailed in the report[15] - No significant mergers or acquisitions were reported during the quarter, with the company emphasizing organic growth strategies[15] - The company has not reported any net profit from merged entities during the current and previous periods, indicating a focus on organic growth rather than acquisitions[22] Earnings Per Share - Basic earnings per share for Q3 2023 were ¥2.18, an increase of 42.48% from the previous year[4] - Basic earnings per share (EPS) increased to ¥6.04 in 2023 from ¥3.91 in 2022, reflecting a growth of 54.5%[22]

证券代码：688617 证券简称：惠泰医疗 公告编号：2023-038 深圳惠泰医疗器械股份有限公司（以下简称"公司"）将于 2023 年 10 月 27 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 7 日（星期二） 上午 11:00-12:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 深圳惠泰医疗器械股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 7 日（星期二）上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：h ...

一、持续督导工作情况 1 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | 7 | 督导上市公司建立健全并有效执行公司 | 保荐机构督促惠泰医疗依照相关规定健 | | | 治理制度，包括但不限于股东大会、董事 | 全完善公司治理制度，并严格执行公司治 | | | 会、监事会议事规则以及董事、监事和高 | 理制度，督导董事、监事、高级管理人员 | | | 级管理人员的行为规范等。 督导上市公司建立健全并有效执行内控 | 遵守行为规范。 | | | 制度，包括但不限于财务管理制度、会计 | 保荐机构对惠泰医疗的内控制度的设计、 | | | 核算制度和内部审计制度，以及募集资金 | 实施和有效性进行了核查，惠泰医疗的内 | | 8 | 使用、关联交易、对外担保、对外投资、 | 控制度符合相关法规要求并得到了有效 | | | 衍生品交易、对子公司的控制等重大经营 | 执行，能够保证公司的规范运行。 | | | 决策的程序与规则等。 | | | | 督导上市公司建立健全并有效执行信息 | | | | 披露制度，审阅信息披露文件及其他相关 | 保荐机构督促惠泰医疗严格执行信息披 | | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 20%[2]. - The company's operating revenue for the first half of 2023 reached ¥787,985,502.65, representing a 41.81% increase compared to ¥555,656,872.82 in the same period last year[17]. - Net profit attributable to shareholders increased by 62.01% to ¥257,395,456.84 from ¥158,872,593.10 year-on-year[19]. - The net cash flow from operating activities surged by 84.17% to ¥331,313,449.87, up from ¥179,897,006.36 in the previous year[19]. - Basic earnings per share rose to ¥3.86, a 62.18% increase from ¥2.38 in the same period last year[18]. - The total profit for the first half of 2023 was approximately ¥291.20 million, an increase of 65.5% from ¥175.84 million in the first half of 2022[181]. - The company reported a comprehensive income total of ¥271,655,171.16 for the first half of 2023, which includes a significant increase in retained earnings of ¥147,904,440.04[190]. Market Expansion and Product Development - The company has provided a performance guidance for the second half of 2023, expecting revenue to grow by 15% to 20% compared to the first half[2]. - New product launches include a next-generation cardiac monitoring device, which is expected to contribute an additional RMB 100 million in revenue by the end of 2023[2]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[2]. - The company is focusing on expanding its peripheral vascular intervention product line, with several products in the registration process, enhancing its market competitiveness[25]. - The company has achieved significant progress in promoting its vascular surgery products, increasing brand recognition in the market[25]. Research and Development - Research and development expenses increased by 25% year-on-year, totaling RMB 50 million, to support innovation in medical technology[2]. - The total R&D investment for the current period is ¥108,927,553.62, an increase of 23.26% compared to ¥88,370,489.51 from the same period last year[43]. - The company has filed 11 new invention patent applications and authorized 3 during the reporting period, with a total of 167 invention patents and 57 authorized patents to date[41]. - The company has developed a complete product line for coronary access products, primarily used in PCI procedures, which includes guiding wires, microcatheters, balloons, and contrast catheters[28]. - The company is committed to continuous R&D investment to align with international standards and expand its product offerings[24]. Regulatory and Compliance Risks - The company has identified potential risks related to regulatory changes in the medical device industry, which could impact future growth[4]. - The company is subject to strict regulatory requirements for its Class III medical devices, which could impact its market access if compliance is not maintained[67]. - The implementation of national centralized procurement policies may lead to price reductions and increased competition in the industry[63]. Shareholder and Governance Matters - The board of directors has confirmed that there are no non-operational fund occupations by controlling shareholders[5]. - The company has not proposed any profit distribution plan for the reporting period[5]. - The company has committed to a profit distribution policy that prioritizes cash dividends, aiming for a minimum cash dividend ratio of 80% during mature stages without significant capital expenditures[128]. - The company has established a commitment to comply with all relevant laws and regulations regarding shareholding and transfers, ensuring transparency and accountability[4]. - The company has committed to long-term promises regarding share restrictions and property rights issues since March 31, 2020[99]. Environmental and Social Responsibility - The company invested approximately 99.19 million yuan in environmental protection during the reporting period[92]. - The company has established an environmental management system and complies with relevant environmental laws and regulations[93]. - The company has not faced any administrative penalties related to environmental issues[93]. Operational Efficiency and Cost Management - Operating costs increased to ¥222,734,109.67, reflecting a year-on-year growth of 35.31%[70]. - The company’s automated production capabilities have significantly improved, contributing to its competitive edge in the market[24]. - The company’s management expenses increased due to rising personnel costs and depreciation from newly established warehouses[72]. Investment and Financial Management - The total amount used for share repurchase will not exceed 2% of the company's total share capital in a single accounting year[112]. - The company’s cash flow from operating activities increased due to growth in business scale and operating profit, resulting in a significant cash flow increase[72]. - The company reported a significant increase in cash flow from operating activities, totaling ¥331,313,449.87, which is an 84.17% increase from the previous year[70].

中信证券股份有限公司 关于深圳惠泰医疗器械股份有限公司 2023 年半年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为深圳 惠泰医疗器械股份有限公司（以下简称"惠泰医疗"或"公司"）首次公开发行 并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所上市公司持续督导工作指引》《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交易所科 创板股票上市规则》《科创板上市公司持续监管办法（试行）》等有关规定，对惠 泰医疗 2023 年半年度募集资金的存放和使用情况进行了专项核查，核查情况如 下： 一、募集资金基本情况 根据中国证券监督管理委员会 2020 年 12 月 7 日核发的《关于同意深圳惠泰 医疗器械股份有限公司首次公开发行股票注册的批复》（证监许可[2020]3359 号）， 公司向社会公众公开发行人民币普通股（A 股）1,667 万股（每股面值人民币 1 元），并于 2021 年 1 月 7 日在上海证券交易所科创板上市（以下简称"本次发 行"）。 本次 发行的 发 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2023-037 深圳惠泰医疗器械股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会 2020 年 12 月 7 日核发的《关于同意深圳惠泰 医疗器械股份有限公司首次公开发行股票注册的批复》（证监许可[2020]3359 号）， 深圳惠泰医疗器械股份有限公司（以下简称"公司"）向社会公众公开发行人民 币普通股（A 股）1,667 万股（每股面值人民币 1 元），并于 2021 年 1 月 7 日在 上海证券交易所科创板上市（以下简称"本次发行"）。本次发行的发行价格为 74.46 元/股，本次发行募集资金总额 1,241,248,200.00 元，扣除公司不含增值税 保荐及承销费以及其他发行费用后募集资金净额为 1,150,717,825.25 元。立信会 计师事务所（特殊普通合伙）2021 年 1 月 4 日出具信会师报字[2021]第 ZA10001 号 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2023-036 深圳惠泰医疗器械股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日以现场结合通讯表决方式召开了第二届监事会第六次会议，会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。本次会议的召集、召开及 表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等有关法 律、行政法规、规范性文件和《深圳惠泰医疗器械股份有限公司章程》的规定， 会议决议合法有效。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于公司<2023年半年度报告>及其摘要的议案》 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的《深 圳惠泰医疗器械股份有限公司 2023 年半年度募集资金存放与实际使用情况的专 项报告》。 特此公告。 表决结果：3 票同意，0 票反对，0 票弃权。 本议案无需提交股东 ...

深圳惠泰医疗器械股份有限公司 独立董事关于第二届董事会第八次会议相关议案的 独立意见 我们作为深圳惠泰医疗器械股份有限公司(以下简称"公司")的独立董事, 根据相关法律、法规、规范性文件以及《深圳惠泰医疗器械股份有限公司章程》 (以下简称"《公司章程》")和《深圳惠泰医疗器械股份有限公司独立董事工 作制度》的规定,基于独立判断的立场,在仔细审阅了第二届董事会第八次会议 的相关文件后,经审慎分析发表如下独立意见: 一、《关于公司<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》 经审阅,我们认为公司董事会编制的《深圳惠泰医疗器械股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告》所载内容真实、准确、完整 地反映了公司的实际情况,不存在任何虚假记载、误导性陈述、重大遗漏。公司 按照相关法律法规、《公司章程》《深圳惠泰医疗器械股份有限公司募集资金管 理制度》的有关要求建立了募集资金专户进行存储和专项使用,不存在变相改变 募集资金用途、违规存放与使用募集资金的情形,也不存在损害公司及股东、尤 其是中小股东利益的情形。 综上,我们一致同意该议案。 (以下无正文) - 1 - (本页无 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2023-035 投资者可于 2023 年 8 月 23 日（星期三）至 8 月 29 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aptmed.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 深圳惠泰医疗器械股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 30 日（星期三）上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ss einfo.com/） 会议召开方式：上证路演中心网络互动 深圳惠泰医疗器械股份有限公司（以下简称"公司"）将于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 8 月 30 日（星期三）上午 ...